Endonovo Therapeutics, Inc. announced it is moving forward in its clinical development in the field of Traumatic Brain Injury (TBI) treatment. The company is actively seeking to collaborate with several renowned clinical researchers and top global cognitive institutes for studies evaluating the effectiveness of SofPulse® in treating TBI patients. The studies will assess the efficacy of SofPulse® to reduce symptoms of TBI resulting from acute head injuries such as concussions and Post-Concussion Syndrome (PCS), including headaches, dizziness and cognitive impairment.

Reaction from TBI Researchers: The company has received an overwhelmingly positive response from clinical researchers regarding the potential effectiveness of its SofPulse® Pulsed Electro Magnetic Field (PEMF) technology in treating TBI. SofPulse® has garnered significant interest from neuroscientists, orthopedic neurologists and cognitive researchers at some of the most prestigious institutions in the world, including Harvard University, Boston's Spaulding Rehabilitation Hospital and Stanford University. Collaboration with top TBI researchers highlights Endonovo's continued commitment in the TBI treatment landscape as it seeks to develop medical technologies to enhance patient outcomes for the treatment of TBI.

Development of new studies evaluating TBI treatments should pave the way for the expansion of the Company's research platform for the further development of its patented PEMF technology. Further research and development in PEMF therapy could lead to its full potential in resolving TBI, Alzheimer's, dementia and ischemic stroke related medical issues. Growing Market for CNS and TBI Treatments: Research suggests that Endonovo's PEMF therapy has the potential to treat Central Nervous System (CNS) disorders and reduce symptoms related to TBI, PCS, MS, dementia, Alzheimer's disease and ischemic stroke.

PEMF Treatments: In past studies, SofPulse® PEMF therapy has demonstrated effectiveness in treating TBI and PCS. The therapy has been found to promote cellular repair, improve blood flow and reduce inflammation in the brain, which is a hallmark of TBI that can lead to severe symptoms such as tissue breakdown, swelling and cell death. PEMF therapy has shown it could also provide a valuable treatment option for athletes in contact-related sports such as football, hockey, boxing and soccer, who are at a higher risk of experiencing TBI.

Refining PEMF treatments for acute and chronic head injuries in these sports could help athletes alleviate the symptoms of TBI and PCS. FDA Clearance and Reimbursement for SofPulse®: Endonovo is dedicated to expanding the use of its SofPulse® technology in the medical field, potentially leading to FDA clearance and medical reimbursement for the treatment of TBI and other inflammatory related CNS conditions. The Company's patents for its PEMF technology cover the method and apparatus for electromagnetic treatment of CNS disorders.

Through continued research and clinical studies, Endonovo aims to demonstrate the efficacy of SofPulse® technology. in reducing inflammation associated with CNS, TBI and PCS. With positive outcomes from TBI studies, the Company's PEMF technology could become a reimbursable treatment option for TBI and PCS, providing an immense market opportunity for Endonovo.